A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
Inclusion Criteria:
Exclusion Criteria:
Chandler, Arizona 85224, United States
Phoenix, Arizona 85013, United States
Phoenix, Arizona 85020, United States
Fremont, Nebraska 68025, United States
Great Neck, New York 11021, United States
Cincinnati, Ohio 45219, United States
Memphis, Tennessee 38120, United States